Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its
Pithampur Unit-1, India facility. The inspection for the facility was conducted by the U.S. FDA between 03 February 2020 and 11 February 2020 and concluded with two observations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
